Fatty Acid Amide Hydrolase (human recombinant)

Stability : 6 months
Formulation :
20 mM Hepes, pH 7.8, 150 mM sodium chloride, 1 mM EDTA, 1 mM DTT, 0.5% CHAPS, and 20% glycerol
Description : 
Fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), resulting in the termination of their biological actions. FAAH, a serine hydrolase, can degrade many fatty acid amides, including AEA. Although FAAH can hydrolyze 2-AG, the main enzyme responsible for the inactivation of this monoglyceride is another serine hydrolase, MAGL. Finding inhibitors to these endocannabinoid hydrolases could offer another approach in the treatment of pain, obesity, and various neurological diseases, where higher endocannabinoid activity would be beneficial. An advantage of such enzyme inhibition over direct cannabinoid agonists could result in higher selectivity, as it would increase activity of the endocannabinoid system only at sites where on-going production of endocannabinoids is taking place.
Purity : 100,000 x g supernatant
Storage : -80°C